Tumor-immune signatures of treatment resistance to brentuximab vedotin with ipilimumab and/or nivolumab in Hodgkin lymphoma.
Gonzalez-Kozlova E, Huang HH, Jegede OA, Tuballes K, Del Valle DM, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Barcessat V, Moravec R, Altreuter J, Duose DY, Kahl BS, Ansell SM, Yu J, Cerami E, Lindsay JR, Wistuba II, Kim-Schulze S, Diefenbach CS, Gnjatic S.
Gonzalez-Kozlova E, et al. Among authors: xie h.
Cancer Res Commun. 2024 Jun 27. doi: 10.1158/2767-9764.CRC-24-0252. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 38934093
Free article.